INBS INTELLIGENT BIO SOLUTIONS INC.
Price Chart
Executive Summary
Intelligent Bio Solutions announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. clearance of its fingerprint drug screening system for codeine. The study will enroll 135 donor participants and 9 operator participants, with data collection expected to complete by end of July 2026. This is a routine clinical milestone with no financial data provided.
Actionable Insight
The filing is a regulatory progress update with no immediate revenue implications. Traders should monitor for study results and FDA submission status in late 2026, but near-term stock movement is unlikely from this announcement alone.
Key Facts
- Multi-site Method Comparison Study initiated for FDA 510(k) submission for codeine assay
- 135 donor participants and 9 operator participants to be enrolled
- Study partnered with CenExel Clinical Research
- Enrollment and data collection expected by end of July 2026
- No financial figures or guidance provided in the filing
Financial Impact
No financial impact disclosed; pre-revenue development-stage company
Risk Factors
- Study results may not support FDA clearance
- Regulatory approval timeline uncertain
- Company has minimal revenue and depends on capital markets
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026780 |
| Exhibit: ex99-1.htm | 0001493152-26-026780 |
| Document: 0001493152-26-026780-index-headers.html | 0001493152-26-026780 |
| Document: 0001493152-26-026780-index.html | 0001493152-26-026780 |
| Document: 0001493152-26-026780.txt | 0001493152-26-026780 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
8-K
| $2.54 $2.44 | ▼ −3.94% | ▼ −3.24% | $2.44 (−3.94%) |
|
Apr 20, 2026
6w ago
|
Press Release
| $2.93 $2.92 | ▼ −0.34% | ▲ +0.31% | $2.44 (−16.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access